GlaxoSmithKline (NYSE:GSK) is one of the globe's largest drug companies. The company generates more than $40 billion in annual sales and, given that its dividend yield is nearly 5%, its shares are often included in dividend investor's portfolios.

Glaxo has a solid track record of dividend increases during the past five years; however, investors are right to wonder whether sliding sales tied to patent expiration may put Glaxo's streak in jeopardy.

In the following slideshow, you'll learn whether I think Glaxo's dividend is safe, and see how Glaxo's dividend matches up to its new consumer goods joint venture partner Novartis (NYSE:NVS) and its competitor AstraZeneca (NYSE:AZN).


Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.